English
Deutsch
Log In
Log in with Fraunhofer Smartcard
Password Login
Research Outputs
Fundings & Projects
Researchers
Institutes
Statistics
Fraunhofer-Gesellschaft
Home
Fraunhofer-Gesellschaft
Scopus
Safety and efficacy of barzolvolimab, an anti-KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: A randomized phase 1b intravenous single dose study
Details
Full
Export
Statistics
Options
Show all metadata (technical view)
2025
Journal Article
Title
Safety and efficacy of barzolvolimab, an anti-KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: A randomized phase 1b intravenous single dose study
Author(s)
Metz, Martin
Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP
Ständer, Sonja
Universitätsklinikum Münster
Moiin, Ali
Revival Research Institute LLC
Nattkemper, Leigh Ann
University of Miami Leonard M. Miller School of Medicine
Bloom, Bradley
Celldex Therapeutics, Inc.
Alvarado, Diego
Celldex Therapeutics, Inc.
Rogalski, Mark
Celldex Therapeutics, Inc.
Lu, Yufang
Celldex Therapeutics, Inc.
Hawthorne, Thomas R.
Celldex Therapeutics, Inc.
Bili, Androniki
Celldex Therapeutics, Inc.
Meltzer-Podolske, Michelle
Celldex Therapeutics, Inc.
Yosipovitch, Gil
University of Miami Leonard M. Miller School of Medicine
Journal
Journal of the American Academy of Dermatology
Open Access
DOI
10.1016/j.jaad.2025.08.022
Additional link
Full text
Language
English
Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP
Keyword(s)
anti-KIT
itch
mast cell
monoclonal antibody
prurigo nodularis
pruritus
stem cell factor
